<DOC>
	<DOC>NCT00518336</DOC>
	<brief_summary>Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IIb study is designed to evaluate the the long-term efficacy, safety and immunogenicity of the 580299 HPV vaccine (CervarixTM) in a Brazilian cohort of women vaccinated in the phase IIb, blinded, primary study 580299/001 (NCT00689741) and having participated in follow-up study 580299/007 (NCT00120848). Only subjects who participated in the primary &amp; follow-up study will be enrolled in this long-term follow-up study. Subjects were aged 15-25 years at the time of entry into the primary study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</brief_summary>
	<brief_title>Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil</brief_title>
	<detailed_description>In this extension study, women who were vaccinated in the primary study, and participated in the follow-up study, will be followed with visits every 6 months.</detailed_description>
	<criteria>Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Subjects who participated in study 580299007. Written informed consent obtained from the subject prior to enrollment. Use or planned use of any investigational or nonregistered product other than the study vaccine. Decoding of the subject's 580299001 treatment allocation to either the subject or the investigator. Administration or planned administration of any other HPV vaccine, other than the vaccine administered in study 580299001.</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>